scholarly journals Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China

2021 ◽  
Vol 8 ◽  
Author(s):  
Xie Xiaohong ◽  
Wang Liqiang ◽  
Li Na ◽  
Lin Xinqing ◽  
Qin Yinyin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Real World ◽  
Protective Factor ◽  
Early Stage ◽  
Therapy Group ◽  
Univariate Analysis ◽  
Anti Cancer ◽  
Ecog Ps

Background and ObjectiveInterstitial lung disease with lung cancer (ILD-LC) is rare and its management has not been fully described. This study aimed to investigate the management and prognosis of ILD-LC patients in China.MethodsThe present analysis is a retrospective real-world cohort study. Clinical data of ILD-LC patients were obtained from 3 hospitals in China. The overall survival (OS) of patients was analyzed. Univariate and multivariate regression analyses were performed.ResultsOne hundred eighty-four ILD-LC patients included were biased toward male (85.3%), smokers (75.5%), idiopathic pulmonary fibrosis (IPF) (58.2%) patients with comorbidities (67.9%) and ECOG-PS score of 1 (65.2%). Most patients were advanced peripheral non-small cell lung cancer. The initial anti-cancer regimen for ILD-LC is mainly chemotherapy, and patients with early-stage LC prefer surgery. In the anti-cancer cohort, the number of ILD-LC patients who underwent the 2nd and 3rd or more anti-cancer regimens were 78 (55.7%) and 32 (22.8%), respectively. In the non-anticancer cohort, the median OS was 3.5 months. In the early-stage cohort, the median OS was 14.2 months in the systematic therapy group; however, the median OS was not reached in the surgery group. In the advanced-stage cohort with systematic therapy, the median OS was 7.2 months. Interstitial pneumonia (IIP) and anti-angiogenesis were associated with OS in the univariate analysis, whereas anti-angiogenesis was an independent protective factor for advanced LC with ILD.ConclusionPatients with ILD-LC have very poor prognosis. Appropriate anti-tumor treatment can prolong the survival time of patients who can tolerate it. Targeted therapy and immunotherapy are alternative treatments for LC patients with mild ILD. For ILD patients with advanced LC, antiangiogenic regimens significantly improve the prognosis of the disease.

scholarly journals Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease

2018 ◽  
Vol Volume 10 ◽  
pp. 7013-7019 ◽  
Author(s):  
Satoshi Igawa ◽  
Noriko Nishinarita ◽  
Akira Takakura ◽  
Takahiro Ozawa ◽  
Shinya Harada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Small Cell Lung Cancer ◽  
Lung Disease ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Weekly Dose ◽  
Small Cell Lung

scholarly journals Stereotactic ablative radiotherapy in patients with early-stage non-small cell lung cancer and co-existing interstitial lung disease

2020 ◽  
Vol 59 (5) ◽  
pp. 569-573 ◽  
Author(s):  
Tobias Finazzi ◽  
Merle I. Ronden-Kianoush ◽  
Femke O. B. Spoelstra ◽  
Esther J. Nossent ◽  
Suzan F. M. Nijman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Small Cell Lung Cancer ◽  
Lung Disease ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Stereotactic Ablative Radiotherapy ◽  
Small Cell Lung

scholarly journals Real world data of combined lung cancer and interstitial lung disease

2019 ◽  
Vol 11 (10) ◽  
pp. 4144-4151 ◽  
Author(s):  
Tatsuo Kawahara ◽  
Hiroyuki Sakashita ◽  
Takafumi Suzuki ◽  
Tomoya Tateishi ◽  
Yasunari Miyazaki
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Real World ◽  
Real World Data ◽  
World Data

scholarly journals Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease

2020 ◽  
Vol 61 (4) ◽  
pp. 563-574
Author(s):  
Yasuhito Hagiwara ◽  
Yuko Nakayama ◽  
Shigehiro Kudo ◽  
Toyokazu Hayakawa ◽  
Naoki Nakamura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Questionnaire Survey ◽  
Radiation Pneumonitis ◽  
Univariate Analysis ◽  
Nationwide Survey ◽  
Fiscal Year ◽  
Computed Tomography Images

Abstract The purpose of this study was to clarify the opinions of radiation oncologists in Japan regarding treatment for lung cancer complicated with interstitial lung disease (ILD) by a questionnaire survey, and the risk of acute exacerbation (AE) after radiotherapy. Questionnaires were sent to all of the facilities in which radiation therapy is performed for lung cancer in Japan by using the mailing list of the Japanese Society for Radiation Oncology (JASTRO). The questionnaire survey was conducted to clarify who judges the existence of ILD, the indications for radiation therapy in cases of ILD-combined lung cancer, and the ratio of ILD-combined lung cancer in lung cancer patients treated with radiation therapy. Patients with ILD-combined lung cancer who received radiotherapy during the period from April 2014 to March 2015 were retrospectively analysed. Any cases of AE without any other obvious cause were included. ILD confirmation was performed by central radiologists using computed tomography images. A total of 47 facilities responded to the questionnaire. Radiation therapy was an option in cases of ILD-combined lung cancer in 39 (83%) of the facilities. The indication for radiation therapy was based on image findings in 35 (90%) of the 39 facilities in which radiation therapy was acceptable or was a choice in some cases of ILD. The final indication was based on the opinion of the pulmonologist in 29 (74%) of those 39 facilities. In fiscal year 2014, a total of 2128 patients in 38 facilities received chest irradiation. Seventy-eight (3.7%) of those 2128 patients had ILD-combined lung cancer. Sixty-seven patients were included in patient analysis. AE occurred in 5 patients (7.5%), and one of those 5 patients (20.0%) died from radiation-induced AE. The median period from radiotherapy to AE was 4 months (range, 2–7 months). The following four independent risk factors for AE were identified in univariate analysis: non-advanced age (<75 years), increased C-reactive protein level (≥0.3 mg/dl), adjuvant chemotherapy and ≥ Grade 2 radiation pneumonitis. Radiotherapy was an option for lung cancer even in cases with ILD in 83% (39/47) of the facilities in Japan. Seventy-eight (3.7%) of 2128 patients who received radiation therapy for lung cancer had ILD. Radiotherapy for ILD-combined lung cancer may induce AE at a substantial rate and AE can be life-threatening. Minimizing the risk of radiation pneumonitis might enable the risk of AE to be reduced.

Sign in / Sign up

Export Citation Format

Share Document